Thin films as an emerging platform for drug delivery  by Karki, Sandeep et al.
Review
Thin films as an emerging platform for
drug delivery
Sandeep Karki a,1, Hyeongmin Kim a,b,c,1, Seon-Jeong Na a,
Dohyun Shin a,c, Kanghee Jo a,c, Jaehwi Lee a,b,c,*
a Pharmaceutical Formulation Design Laboratory, College of Pharmacy, Chung-Ang University, Seoul 06974,
Republic of Korea
b Bio-Integration Research Center for Nutra-Pharmaceutical Epigenetics, Chung-Ang University, Seoul 06974,
Republic of Korea
c Center for Metareceptome Research, Chung-Ang University, Seoul 06974, Republic of Korea
A R T I C L E I N F O
Article history:
Received 21 April 2016
Accepted 12 May 2016
Available online 6 June 2016
A B S T R A C T
Pharmaceutical scientists throughout the world are trying to explore thin films as a novel
drug delivery tool. Thin films have been identified as an alternative approach to conven-
tional dosage forms. The thin films are considered to be convenient to swallow, self-
administrable, and fast dissolving dosage form, all of which make it as a versatile platform
for drug delivery. This delivery system has been used for both systemic and local action via
several routes such as oral, buccal, sublingual, ocular, and transdermal routes. The design
of efficient thin films requires a comprehensive knowledge of the pharmacological and phar-
maceutical properties of drugs and polymers along with an appropriate selection of
manufacturing processes. Therefore, the aim of this review is to provide an overview of the
critical factors affecting the formulation of thin films, including the physico-chemical prop-
erties of polymers and drugs, anatomical and physiological constraints, as well as the
characterization methods and quality specifications to circumvent the difficulties associ-
ated with formulation design. It also highlights the recent trends and perspectives to develop
thin film products by various companies.
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1. Introduction
Generally, thin films can be referred as a thin and flexible layer
of polymer with or without a plasticizer [1]. Since they are thin
and flexible by their nature, it can be perceived to be less ob-
trusive and more acceptable by the patient [2]. The thin film
is polymeric matrices that meet many requirements for being
used efficiently as a drug release platform [3]. Fundamen-
tally, thin films are excellent candidates for targeting sensitive
site that may not be possible with tablets or liquid formula-
tions [4]. Thin films have shown the capabilities to improve the
onset of drug action, reduce the dose frequency and enhance
the drug efficacy [3]. Similarly, thin films may be useful for elimi-
nating side effects of a drug and reducing extensive metabolism
caused by proteolytic enzymes [5,6]. Ideal thin films need to
exhibit desirable features such as sufficient drug loading ca-
pacity, fast dissolution rate or long residence time at the site
of administration, and acceptable formulation stability. They
should also be non-toxic, biocompatible and biodegradable [7,8].
Compared with the existing traditional dosage forms, it
stands out to be superior in terms of enhanced bioavailability,
high patient compliance, and patent extension of active phar-
maceutical ingredients (API) [9]. Furthermore, thin film
formulations offer several advantages, including (a) conve-
nient administration through non-invasive routes, (b) ease of
handling during manufacture and transportation, and (c) cost-
effectiveness in the development of formulations [8,10,11]. The
availability of a wide array of suitable polymers and the para-
digm shift in manufacturing technology have made possible
to develop a wide range of thin films [12]. Therefore, a thin film
is gaining popularity and acceptance in the pharmaceutical
arena as a novel drug delivery dosage form.
Substantial efforts have been made to formulate polymeric
thin films that are administered generally via buccal, sublin-
gual, ocular and skin routes [13,14].Among different routes, the
use of thin films for delivering medicine into sublingual or buccal
mucosa has drawn immense interest in recent years [15]. Mean-
while, ophthalmic films are currently developed for overcoming
the ocular barriers and preventing loss of drugs through the
lacrimal drainage system [16]. Controlling compositions of
polymers of different grades has facilitated the modification of
key characteristics of thin films such as drug release rate,
mucoadhesive properties, mechanical strength and other related
properties.Additionally, various inactive components can be in-
cluded such as fillers, plasticizer, saliva stimulating agent,
colorants, and sweeteners for improving aesthetic characteris-
tics. Many pharmaceutical companies are fascinated by the
appealing features of thin films, and as a result they have already
patented various technologies for producing thin films [17].
Currently, a significant amount of original works and patents
can be found in literature, but still there is a need for exten-
sive studies to optimize the performance of thin films
accurately. The lack of appropriate guidance for the manufac-
ture, characterization and quality control of the thin films has
sought the need of adequate studies in this area from the phar-
maceutical viewpoint. Therefore, this paper will contribute to
give insights on understanding the critical quality attributes
and characterization methods with the aim to enhance the per-
formance of thin films.
2. Types of thin films
Thin film is not a recent formulation, and it was first intro-
duced in late 1970 to overcome swallowing difficulties exhibited
by tablets and capsules [15]. Various names of thin films ap-
peared, such as oral film (oral thin film), oral soluble film, wafer,
oral strip, orodispersible film (ODF), buccal film, mucoadhesive
film, ophthalmic film, and transmucosal film.While several films
are designed to be dissolved quickly in the oral cavity for the
absorption of a drug in the gastrointestinal cavity (oral and oral
soluble, or orodispersible films), some are prepared to deliver
a drug at the site of administration (e.g., buccal, sublingual and
ophthalmic thin films). Drugs with high mucosal permeability
have been known to be suitable for buccal and sublingual de-
livery with films [18]. Likewise, ophthalmic thin films are
generally applied to treat diseases of the anterior segment such
as conjunctivitis,glaucoma and chronic dry eye syndromes [5,19].
A film that readily dissolves in the oral cavity is generally
termed as orodispersible film according to European Medi-
cines Agency (EMA) or simply soluble film according to FDA
[3]. Usually, fast dissolving oral films are ultra-thin film (50–
150 μm) having size of postage stamp, which dissolves within
a minute in the oral cavity after being in contact with the saliva,
resulting in quick absorption and instant bioavailability of the
drugs [20,21]. Drugs loaded in buccal adhesive films are ab-
sorbed directly via buccal mucosa, which delivers the drug to
the systemic circulation after their absorption [22]. Likewise,
wafer is frequently mentioned as paper-thin polymeric films
employed as carriers for pharmaceutical agents. This innova-
tive dosage form is taken orally but does not require water to
swallow for the absorption of a drug [23]. Orodispersible films
should not be misunderstood with buccal films designed for
staying longer on the cheek mucosa [24]. Therefore, different
types of films should be distinguished accurately to prevent
possible misinterpretations.
3. Advantages of thin films as an emerging
dosage form
3.1. Advantages over conventional dosage forms
A thin film dissolves rapidly than other conventional dosage
forms [25]. Thin films are less friable and easy to carry dosage
form compared to commercialized orally fast disintegrating
tablets, which need special packing. Likewise, a single dose of
strip can be carried individually without requiring the sec-
ondary container [26,27]. It is very important to address the
poor stability of liquid dosage forms, especially the aqueous
formulations. Unlike the thin films, there is a need for great
care during accurate measurement of the amount and shaking
the bottle every time before administration may contribute to
less acceptance by the patients [3]. Conventional ophthalmic
drug delivery systems such as eye drops or solutions are
commonly used but they are limited in their ability to provide
high ocular drug bioavailability and sustained duration of action
[28]. Ophthalmic thin films can be used to improve the drug
delivery to the eye. In contrast to transdermal patch, the trans-
dermal film is less associated with skin irritation due to less
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occlusive properties that improve the water vapor perme-
ation through the skin and do not leave sticky sensation on
the site of application [29,30].
3.2. Clinical advantages
Patients show preference toward thin film due to its appella-
tive form and ease of administration [17]. Furthermore, oral
dissolving film is extensively useful for pediatric, geriatric, and
psychiatric patients since it is easy to administer and avoid
the risk of choking or suffocation, thus ensuring patient safety
[22]. Ophthalmic films have been known to enhance the re-
tention time of a drug, and thereby the absorption of the
drug was greatly improved from the anterior segment of the
eye [31]. Moreover, the polymeric thin films can also be ben-
eficial for bedridden and non-cooperative patients as they can
be administered easily and hardly spit out. A thin film is useful
in cases where a rapid onset of action is required, such as in
motion sickness, sudden episodes of allergic attack or cough-
ing, bronchitis or asthma [22].
4. Major limitations of thin films
Use of thin films is sometimes limited largely due to low drug
loading capacity for a less potent drug given at high dose [10].
Thin films are usually hygroscopic in nature. Thus, special
precaution should be taken for their longer preservation [4].
Combining more than one drug concomitantly is a very chal-
lenging task in oral film formulation because both the dissolution
rate as well as the disintegration time are hindered by the co-
administration of a drug in oral films [32].The difficulty to obtain
a high degree of accuracy with respect to the amount of drug
in individual unit dose of the film can lead to therapeutic failure,
non-reproducible effects and sometimes toxic effects to the
patient [33]. Preparing oral film formulation is concerned with
the issues of requiring excessive time for drying. It takes around
one day for the complete drying at room temperature, which
notably decreases the rate of production of films. Since it is
not recommended to use hot air oven for thermolabile drugs,
an alternative process of drying should be explored [22].
5. Polymers for the preparation of thin films
Polymers are the backbone of film formulations and various
polymers are available for the preparation of thin films [34].
The polymers can be used alone or in combination with other
polymers to achieve the desired film properties. The poly-
mers employed should be non-toxic, non-irritant, and absence
of leachable impurities is required. Water-soluble polymers are
used as film formers to produce a thin film with rapid disin-
tegration, good mechanical strength, and good mouthfeel
effects. Both natural and synthetic polymers are used for film
preparation [20,35]. The list of polymers commonly used in the
manufacture of polymeric films, with additional descriptions
and properties, is depicted in Table 1.
Availability of diverse polymers allows imparting specific prop-
erties in the thin films. For instance, gelatins are available in
different molecular weights, and thus the appealing and glossy
films could be obtained with the gelatin having a high molecu-
lar weight. Pullulan is frequently used for producing a thin film
with great solubility,high mechanical strength and they are stable
over a wide range of temperatures.The blending of chitosan and
high methoxy pectin (HMP) or low methoxy pectin (LMP) re-
sulted in a thin film exhibiting an excellent mechanical strength.
The film forming polymers such as hydroxypropyl cellulose (HPC),
methyl cellulose, and carboxymethyl cellulose (CMC) produce
a thin film with less water vapor barrier due to hydrophilic nature
which aids in water retention [15].
In one study, a fast-dissolving film of triclosan was pre-
pared using different grades of hydroxypropyl methylcellulose
(HPMC) named as Methocel E3, Methocel E5, and Methocel
E15 Premium LV as a primary film former. The result demon-
strated that Methocel E5 Premium LV at the concentration of
2.2% w/v produced films with excellent film properties [37].The
in vitro residence time of the film made from Carbopol® 934P
and HPMC E15 was almost double than the films containing
only HPMC E15. Additionally, it was observed that the com-
bined polymers were more resistant to breakage [11]. Cilurzo
et al. reported the use of maltodextrins (MDX) with low dex-
trose content as a film forming polymer for the preparation of
oral fast-dissolving films of an insoluble drug, piroxicam. Despite
the decrease in film ductility due to the loading of the drug as
a powder, the produced film exhibited satisfactory flexibility
and resistance to elongation along with rapid dissolution [38].
Similarly, oral dissolving films of granisetron HCl manufac-
tured using HPMC and pullulan illustrated the effect of increasing
polymer concentration on mechanical properties and physi-
cal properties of films. Pullulan with 40–45% concentration was
not able to produce films with good strength whereas the HPMC
used in 40% concentration yielded the film which was diffi-
cult to peel. Likewise, the film stickiness increased when the
concentration of HPMC was beyond 50% [39].
Mucoadhesive films are thin and flexible retentive dosage
forms, and release drug directly into a biological substrate.They
facilitate in extending residence time at the application site
leading to prolonged therapeutic effects [40]. Majority of the thin
film having mucoadhesive properties are hydrophilic in nature
and undergoes swelling and form a chain interaction with the
mucin [11].Among the several studied polymers, the most com-
pelling mucoadhesion properties are exhibited by chitosan,
hyaluronan, cellulose derivatives, polyacrylates, alginate, gelatin
and pectin [41]. Compared with non-ionic polymers, the cat-
ionic and anionic polymers facilitate strong interaction with
mucus [42]. Anionic polymers are well characterized due to the
existence of carboxyl and sulfate functional groups, which
create the negative charge at pH values surpassing the pKa
of the polymer. As an example, sodium carboxymethyl cellu-
lose (NaCMC) and polyacrylic acid (PAA) exhibit excellent
mucoadhesive properties because of bond formation with the
mucin [43].Thiomers, i.e. polymer containing thiol group, stand
out to enhance mucoadhesion because they are able to interact
with the mucin through the formation of disulfide linkages.
The process of ‘thiloation’ is possible with many polymers,
using amide-coupling chemistry, where the aqueous solvent
systems are used [44].Eudragit displayed promising mucoadhesive
properties when used alone or in combination with other hy-
drophilic polymers. Films, prepared from the propranolol HCl,
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Table 1 – Properties and key findings of representative polymers used for preparation of thin film formulations.
Polymer Properties Key findings References
Hydroxypropyl
methylcellulose
(HPMC)
• White, creamy, odorless, and tasteless powder
• Mw 10,000–1,500,000
• Soluble in cold water, but insoluble in chloroform
and ethanol
• Viscosity (η) 3–100,000 mPa·s
• Non-ionic polymer with moderate
mucoadhesive properties
• Solutions are stable at pH 3.0 to 11.0
• Film forming ability at 2–20% concentrations
• Generally used for controlled and/or delayed
release of the drug substance
• Initial burst drug release followed by slow or
sustained drug release diffusion observed in buccal
bioadhesive system of nicotine hydrogen tartrate
[3,11,17,36]
Carboxymethyl
cellulose (CMC)
• White, odorless powder
• Mw 90,000–700,000
• Easily dispersed in water to form a clear or
colloidal solution
• η 5–13,000 mPa·s (1% aqueous solution)
• High swelling properties
• Good bioadhesive strength
• Improved the residence time of HPC and sodium
alginate films
• Good compatibility with starch forming
single-phase polymeric matrix films with improved
mechanical and barrier properties
• The enzymatically modified CMC has good film
forming property
[3,11,17,36]
Hydroxypropyl
cellulose (HPC)
• White to slightly yellow colored, odorless, inert
and tasteless powder
• Mw 50,000–1,250,000
• Soluble in cold and hot polar organic solvents
such as absolute ethanol, methanol, isopropyl
alcohol and propylene glycol
• η 75–6500 mPa·s depending upon the
polymer grade
• Moderate mucoadhesive properties
• Used to replace synthetic polymers or HPMC in a
polymer matrix with modified starch to improve
solubility
• It has a good film forming property and 5% (w/w)
solution is generally used for film coating
• Zero-order release kinetics of lidocaine and
clotrimazole associated with erosion square-root of
time release kinetics of lidocaine
[3,11,17,36]
Poly (vinyl
pyrrolidone)
(PVP)
• Wide range of solubility
• Non-ionic
• High swelling properties
• Used as co-adjuvant to increase mucoadhesion
• Blending of PVP with PVA and HPMC improves film
forming ability
• Blended with ethyl cellulose and HPC produces
films with increased flexibility, softer and tougher
properties
• Different ratios of PVP-alginate blends can be used
to design drug controlled release
• As film-forming polymer exhibited non-Fickian
release of ketorolac and progesterone
[3,11]
Poly (vinyl
alcohol) (PVA)
• White to cream-colored granular powder
• Mw 20,000–200,000
• Water soluble synthetic polymer
• Non-ionic polymer
• Moderate mucoadhesive properties
• Very flexible films
• Mainly used in ophthalmic polymeric preparations
at concentration of 3–5%
• Higher elongation at break values
[3]
Poly (ethylene
oxide) (PEO)
• Non-ionic polymer
• High mucoadhesion with high molecular weight
• Optimization of tear resistance, dissolution rate,
and adhesion tendencies of film by combining low
Mw PEO, with a higher Mw PEO and/or with
cellulose
• Films with good resistance to tearing, minimal or
no curling
• Pleasant mouth feeling with no sticky or highly
viscous gel formation
[3,11]
Pullulan • White, odorless, and tasteless powder
• Mw 8000–2,000,000
• Soluble in hot as well as cold water
• η 100–180 mm2/s (10% aqueous solution at 30 °C)
• Contain > 6% w/w of moisture
• Blending with sodium alginate and/or CMC may
synergistically enhance the properties of the film
• Pullulan–HPMC films have improved thermal and
mechanical properties
• 5–25% (w/w) solution forms flexible films
• Stable film with less permeability to oxygen
[3,17]
Pectin • A yellowish white, odorless powder with
mucilaginous taste
• Mw 30,000–100,000
• Soluble in water but insoluble in most of the
organic solvents
• Strong mucoadhesive properties
• Not very useful for fast dissolving films, but
modified pectins yielded films with fast
dissolution rates
• Good film forming capacity at low temperature
• Brittle and do not have a clear plastic deformation
[3,17]
Chitosan • White or creamy powder or flakes, and odorless
• Obtained after partial deacetylation of chitin
• Biocompatible and biodegradable
• Sparingly soluble in water; practically insoluble in
ethanol (95%), other organic solvents, and neutral or
alkali solutions at pH above approximately 6.5
• Excellent film forming ability
• Chitosan enhances the transport of polar drugs
across epithelial surfaces
• Possesses cell-binding activity due to polymer
cationic polyelectrolyte structure that binds to the
negative charge of the cell surface
[11,36]
(continued on next page)
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Eudragit RS100, and triethyl citrate (plasticizer), demonstrated
mucoadhesive force three times greater than the film prepared
with chitosan as the mucoadhesive polymer [11]. Juliano et al.
prepared a buccoadhesive films consisting of alginate and/or
HPMC and/or chitosan either as a single polymer or in a com-
bination of two. Basically, they aimed the films to release the
chlorhexidine diacetate in a controlled manner. HPMC was not
able to prolong the chlorhexidine release as more than 80% of
the drug was released within only 30 min.However,chlorhexidine
incorporated in alginate and alginate/chitosan-based films showed
that only 30–35% of the drug was released in 30 min; hence, this
polymeric system is beneficial for prolonged drug release [45].
In common terms, polymers are understood as excipi-
ents, but it has become an essential component while designing
and formulating thin films. Therefore, understanding the prop-
erties of polymers such as chemistry, rheology, and physico-
chemical properties of polymer seems to be imminent for
maximizing their uses to develop a thin film. The selection of
appropriate polymer during the development of polymeric thin
films may be critical; thereby, several points should be con-
sidered according to the requirements.Therefore, it is imperative
to consider the appropriate polymer for producing a thin film
with a better performance that assures high therapeutic success.
6. Technologies for manufacturing thin films
The most commonly used techniques for the preparation of
thin films are solvent casting [46,47] and hot melt extrusion
[38,48]. However, an innovative technique like inkjet printing
[49] has evolved in the past few years. Various methods that
have been employed for polymeric thin film manufacturing are
described below in detail:
6.1. Solvent casting
Among several techniques of film manufacturing, solvent
casting is feasible, preferable and undoubtedly widely used
method mainly due to the straightforward manufacturing
process and low cost of processing. The manufacturing pro-
cedure of thin films with the solvent casting method along with
the quality control parameters in each step is illustrated in Fig. 1.
The rheological properties of the polymeric mixture should be
taken into account since they affect the drying rate, the film
Table 1 – (continued)
Polymer Properties Key findings References
Sodium alginate • Occurs as a white or buff powder, which is
odorless and tasteless
• Purified carbohydrate product extracted from
brown seaweed by the use of dilute alkali
• Insoluble in other organic solvents and acids
where the pH of the resulting solution falls
below 3.0
• η 20–400 Cps (1% aqueous solution)
• Anionic with high mucoadhesive properties
• Safe, biodegradable and non-allergenic
• Rapid swelling and dissolution in water
• Used as immobilization matrices for cells and
enzymes, controlled release of bioactive substances
• Excellent gel and film forming properties
• Compatible with most water-soluble thickeners
and resins
[11,36]
Carrageenan • An anionic polysaccharide, extracted from the red
seaweed Chondrus crispus
• Three structural types exist: Iota, Kappa, and
Lambda, differing in solubility and rheology
• The sodium form of all three types is soluble in
both cold and hot water
• The best solution stability occurs at pH 6 to 10
• Moderate mucoadhesive properties
• Potential to act as protein/peptide stabilizer by
steric stabilization
• It is compatible with most nonionic and anionic
water soluble thickeners
• Solutions are susceptible to shear and heat
degradation
[6,11,36]
Gelatin • A light amber to faintly yellow colored powder
• Mw 15,000–250,000
• Soluble in glycerin, acid, alkali and hot water
• η 4.3–4.7 mPa·s (6.67% (w/v) aqueous solution
at 60 °C)
• Moisture content 9–11% (w/w)
• It has a very good film forming ability
• Useable for preparation of sterile film, ophthalmic
film, and sterile sponge
[17]
Fig. 1 – Solvent casting method for film preparation with
quality control parameters in each step.
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thickness, the morphology as well as the content uniformity
of the films [26]. The mixing process could introduce the air
bubbles into the liquid inadvertently; therefore, de-aeration is
a pre-requisite to obtain a homogeneous product [17]. After
casting the solution into a suitable substrate, they are left for
drying to allow the solvent to evaporate, which just leaves a
polymeric film with a drug on it [2].
After the complete drying of the film, it is cut into suitable
shape and size depending upon the required dosage of the formed
strip. In the majority of the cases, the strips are rolled and stored
for a certain time before cutting, which is known as ‘rollstock’
in an industry. However, a film should not be exposed for too
long time since it is prone for being damaged. If possible, it should
be cut and packed immediately after the preparation to keep
its stability [17]. Several advantages such as better physical prop-
erties, easy and low cost processing, and excellent uniformity
of thickness are observed with the film obtained by solvent-
casting [50]. However, this process suffers from some limitation.
For instance, a polymeric thin film prepared by solvent casting
method was brittle upon storage, as marked by decrease in the
percent elongation due to evaporation or loss of the residual
solvent in the film over time [51]. Another issue under scrutiny
associated with this method is the requirement of using organic
solvents. The presence of organic solvent system is a serious
problem because it causes a hazard to health and environ-
ment.As a result, strict regulations have been adopted by many
countries regarding the use of an organic solvent [11].
Translating the production of films from a bench scale to
production scale is one of the biggest challenges because many
factors such as heating, mixing speed, and temperature could
bring variability in quality, and consistent formation of films
in commercial scale may not be possible. Therefore, suffi-
cient endeavor should be invested to optimize the various
parameters such as the speed of casting, drying time, and final
thickness of the dried strip, which may affect the production
of films from commercial scale output [17]. Fig. 2 depicts the
machine that is used for a large-scale production of film based
on solvent casting technique.
6.2. Hot-melt extrusion (HME)
HME is a versatile method adopted for the manufacture of gran-
ules, tablets, pellets [52], and also thin films [38]. It is a substitute
method to solvent casting for the preparation of the film, es-
pecially useful when no organic solvent system is required [10].
However, only few literature has reported the use of hot-melt
extrusion for the preparation of polymeric thin films [11]. HME
is a process of shaping a mixture of polymers, drug sub-
stance, and other excipients into a film by melting all the
components [3]. Eventually, the films are cut into a particular
shape and dimensions [6]. In this method, a mixture of phar-
maceutical ingredients is molten and then charged through
an orifice (the die) to obtain homogeneous matrices [11]. Since
APIs are subjected to operation at high temperature with
complete absence of solvents, this method is not suitable for
thermos-labile APIs [17]. The practical steps of HME are out-
lined as follows [53]:
(1) Feeding of the components to the extruder through
a hopper,
(2) Mixing, grinding, and kneading,
(3) Flowing the molten and blended mass to the die, and
(4) Extruding the mass through the die and further down-
stream processing.
The equipment for the process of HME is illustrated in Fig. 3,
which consists of the hopper, extruder, film die, and roller. The
extruder contains one or two rotating screws (co-rotating or
counter rotating) inside a static cylindrical barrel. The barrel is
often manufactured in sections to shorten the residence time
of the molten material.The sectioned part of the barrel is either
Fig. 2 – Commercial manufacturing of film based on solvent-casting (reproduced from Ref. [22]).
Fig. 3 – Hot-melt extrusion system for the preparation of
films (reproduced from Ref. [22]).
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bolted or clamped together.Similarly, the end portion of the barrel
is connected to the end-plate die, which is interchangeable de-
pending upon the required shape of the extruded materials [1].
With regard to the advantages of HME, it produces a drug
in the form of solid dispersion or solution, which could improve
solubility of poorly soluble drugs [51]. However, at elevated tem-
perature, there is a high chance of recrystallization of API in
the polymer blend as the temperature drop. Using highly viscous
polymeric substance or increasing the amount of plasticizer
can prevent this problem. Another issue of HME is the “Die swell
phenomenon,” i.e. an increase in the cross-section of the film
after ejection from the die depending on the viscoelastic char-
acteristics of polymers.This is due to the polymer withstanding
high energy kneading and high shear force during extrusion.
This problem can be prevented by slowing the speed of screw
operation or by gently mixing molten mass for a long time
instead of high shear kneading for a short duration [54]. Unlike
solvent casting, this method avoids the need of organic solvent;
hence, they are proven to be environment friendly [2].
6.3. Printing technologies
Novel methods such as 3D printing could be used for manu-
facturing polymeric thin films. It could potentially be a platform
for producing the dosage form beneficial to the individual
patient. This possibly will resolve the issue of the pharmaceu-
tical industry and pharmacies to meet the future demand of
customized medicine [55]. The printing technologies are in-
creasingly gaining popularity because of its flexibility and cost-
effectiveness. From the viewpoint of pharmaceutical industry,
printing technologies are commonly in practice for identify-
ing or labeling of the pharmaceutical dosage forms, particularly
to optimize the product to be readily identified and to prevent
counterfeit production. However, this approach has recently
been adopted for the drug loading of pharmaceutical dosage
forms [3]. The examples include the use of off-the-shelf con-
sumer inkjet printers in which drug-loaded inks are deposited
to yield accurately dosed units of pharmaceutical ingredi-
ents. In addition, a combination of inkjet and flexographic
technologies has been practiced as well [55]. The inkjet print-
ing was used for printing of API on different substrate, whereas
the flexographic printing was employed to coat the drug loaded-
substrate with a polymeric thin film [56].
Loading of drug substances into transdermal patches is pos-
sible via screen printing and pad printing; however, pad printing
is limited by the low speed of production. In recent years, inkjet
printing has made inroads for preparation of film formulation
as a safe and accurate method to produce dosage form of potent
drug administered at low dose [57]. Preparation of multiple layers
can be done by adding a second printing layer on the top of
the first with or without an intermediate base film layer. Further,
the printed layer would be shielded by a second base film layer.
This will result in modified drug release profiles and protect
the ink layer from detachment or mechanical stress during pro-
cessing like cutting or packaging area [55].
Regardless of the various types of printing technique
used, all of them contribute to producing a film with more ho-
mogeneous distribution and accurate dosage of the drug
throughout the films. The dose accuracy and uniform distri-
bution of the drug substances in the films are accounted for
several reasons, such as coating mass properties, like viscos-
ity or density, which are inherently influenced by the amount
and characteristics of the processed drug substances. With
regard to the conventional method of film preparation, it may
be very challenging to ensure the same dosage accuracy in the
individual units [3]. To summarize, printing a drug on dosage
form is the latest intervention for film preparation and it has
become a powerful tool to manufacture dosage form with ex-
cellent uniformity, speed-ability, and stability. Representing
printing technologies that have been used for preparation of
polymeric thin films are discussed below.
6.3.1. Inkjet printing
Inkjet printing is the recently developed technology, which is
characterized by its versatility, accuracy, repeatability and rela-
tively inexpensive method that deposits small volumes of
solution in films. Inkjet printing is extensively applicable for
the preparation of low dose medicines and also offers an op-
portunity to manufacture personalized medicines [58].
Inkjet technology is usually divided into mainly two types:
(a) continuous inkjet printing (CIP) and (b) drop on demand
(DoD) printing. Both are different in their printing process by
which the drops are generated. In the case of CIP, there is a
consistent ejection of a liquid through an orifice (nozzle), and
it breaks up into a stream of drops under the force of surface
tension. For the continuous production of a stream of ink-
drops, the individual drop should be ‘steered’ to a particular
landing site to produce a printed pattern. This is possible by
applying an electric charge on some of the drops that deflect
the stream from the main axis under an electrostatic field. On
the other hand, ejection of the liquid from the printhead occurs
in drop-on-demand printing only when a drop is needed. The
production of individual drop takes place rapidly under the re-
sponse of trigger signal. A DoD printhead consists of multiple
nozzles (ranges from 100 to 1000, even though specialist
printhead may have a single nozzle). The drop ejection occurs
due to the kinetic energy of drops generated from the source
located in the printhead nearby to each nozzle [59].
The uniform distribution and dose accuracy of the drug sub-
stance in the film rely upon the density or viscosity of the ink
(drug substance solution or suspension), which determine the
printability characteristics [3]. Janßen et al. demonstrated
the deposition of low doses of salbutamol sulfate onto com-
mercially available starch-based film using conventional desktop
printers [10]. However, inkjet printing is not applicable for high-
throughput industrial production, instead using of flexographic
printing is regarded more suitable for industrial preparation.
6.3.2. Flexographic printing technology (FPT)
FPT is a process that transfers active pharmaceutical ingredi-
ent into thin films gently via contact printing [10]. The
flexographic printing is a rotary printing process as depicted
in Fig. 4, where ink consisting of drug substance solution and
suspension is measured by an anilox roller, then are trans-
ferred to a printing cylinder that prints the film after unwinding
the daughter roll [3]. It is useful for heat sensitive products
like proteins and peptides. As the mixing and drying of film
formulation are processed before introducing the drug, the prob-
lems such as loss of activity of API can be prevented. The
production efficiency is also high considering the production
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rate of 530 oral films per minute; hence, this process could be
expanded to scale-up production [6]. No effect on the me-
chanical properties of polymeric thin films upon printing drug
solutions was witnessed using flexographic printing [57]. In a
study, Janßen et al. found that it was possible to dispense
tadalafil and rasagiline mesylate solution onto hydroxypropyl
methylcellulose films using flexographic printing. The intro-
duction of hydroxypropyl cellulose appeared to reduce drug
crystallization after printing. However, the main drawbacks of
flexography are relatively low resolution, high chances of con-
tamination, and the need to prepare a print roller, which is not
suitable for large scale production [10].
7. Quality issues of thin films
For being regarded as an ideal thin film, a film should have ad-
equate flexibility, softness, elasticity, and good physico-
chemical stability. Therefore, all these parameters should be
considered carefully while developing film to ensure its effi-
cient performance. Characterization of a film is a pre-requisite
that may include assessing properties such as mechanical
strength, hydration, in vitro release and surface morphology.
The following section outlines the various critical quality at-
tributes affecting film properties and commonly used in vitro
methods for film characterization.
7.1. Thickness and weight variation
The measurement of thickness is necessary as it directly
correlates with the amount of drug in the film. In addition, an
appropriate thickness is required for the comfortable admin-
istration of films. For instance, the ideal thickness of buccal
films should be in the range of 50 to 1000 μm [12]. Generally,
the thickness of the formed thin films is measured using Vernier
caliper, electronic digital micrometer, screw gauge, or scan-
ning electron microscopy (SEM) images [60,61]. The amount of
plasticizer in the formulation is known to increase the film
thickness slightly [62]. By inserting m (Batch) – the mass of the
whole batch, m (API/film) – the drug amount per film, ρ (Batch)
– the density of the formulation, m (API) – the total drug amount
in the batch and A (Film) – the area of one film in Eq. (1), it is
possible to calculate the casting thickness (h). A correction factor
f is added due to the shift of actual value of film thickness
compared to the set values. A shift behavior is defined before-
hand over different coating thicknesses [63].
H m f
m Batch m API film
Batch m API A Film
μ
ρ
( ) = ( ) ×( ) × ( ) × ( ) +
( ) × 10 000, (1)
where API is active pharmaceutical ingredient, m is mass, ρ
is density, and A is area expressed in g, g/cm3, and cm2
respectively.
The weight variation is generally determined to ensure that
each film contains the consistent amount of a drug without
significant deviation. It is calculated by weighing the indi-
vidual film and the average weights of specified films
respectively. The average weight of film is subtracted from the
individual weight of patches. The mean ± SD values are cal-
culated for all the formulations. A large variation in weight
signifies the inefficiency of the method applied and high
chances are there for non-uniformity in drug content [12].
7.2. Mechanical and physical properties
Polymeric films should possess enough tension so that it can
be ejected easily from the pouch, rolled up after casting, and
peeled from the release liner, but should not be too flexible
because greater elongation during cutting and packaging might
cause variation in film amount resulting in non-uniformity of
API amount per film [49,64]. Mechanical properties of films can
be defined in terms of Young’s modulus, percent elongations,
tensile strength and tear resistance [64,65]. It has been known
that soft and weak polymers exhibit low tensile strength, low
elongation at break and low Young’s modulus, whereas the hard
and tough polymer have a high tensile strength, high elonga-
tion at break and high Young’s modulus [11]. Additionally, the
mechanical properties of films are affected by the method of
manufacturing and the formulation. Some general behaviors
of films observed from stress—strain curves are shown in Fig. 5
[6]. The concentration and types of the polymers are largely
responsible for producing a film having good mechanical
strength and integrity [66]. Likewise, the morphological state
of the film may alter the mechanical strength, e.g. by crystal
growth [64]. Therefore, different factors such as film-forming
agent, type of manufacturing process, thickness of film and the
type and amount of API in the film have to be considered care-
fully for controlling the mechanical strength of the film.
Blending and cross-linking of two or more polymers are
useful methods to improve the mechanical properties of the
combined polymeric mix [67]. The film maintains their ap-
pearance and integrity after cross-linking, but hardening of the
film surface can occur [68]. Consistent with this observation,
the mechanical properties of PVA–NaCMC films were greater
Fig. 4 – Schematic overview of flexography technology for the preparation of films (reproduced from Ref. [57]).
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than film composed of PVA or NaCMC alone. The tensile
strength of PVA–NaCMC film was found to be 13 to 17 times
greater than those of films made of the synthetic polymer
N-vinylpyrrolidone [69,70]. Use of plasticizer may overcome the
brittleness and soften the rigidity of the film structure by re-
ducing the intermolecular forces. The most commonly used
plasticizer are glycerol, sorbitol, propylene glycol and polyeth-
ylene glycol [66,71]. However, using too much amount of
plasticizer can decrease the adhesive strength of films by over-
hydrating the film formulations [72]. For example, glycerin
intercalates themselves between every individual strand of
polymer, thereby causing disruption of polymer–polymer in-
teraction.The tertiary structure of the polymers is changed into
more flexible and porous type. For this reason, the plasti-
cized polymer deforms at lower tensile strength compared with
a polymer without plasticizer [73].
In most of the works of literature, the most commonly used
method for characterizing the mechanical strength of a poly-
meric film is carried out by using texture analyzer. The system
starts measuring force and displacement of the probe when
they are in contact with the sample. There is an individual
sample holder to aid measurement of small-sized film samples
(Fig. 6). Films are attached by screws between two plates with
a cylindrical hole of required diameter. The plate is stabilized
to avoid movements using pins, which are placed centrally
beneath the punch. The adjustment can be made to move the
probe forward according to required working velocity.The mea-
surement starts after the probe is in contact with the sample
surface (triggering force).The movement of probe occurs at con-
stant fixed speed until the film detaches. At last, the applied
force and displacement (penetration depth) should be re-
corded along with the room temperature and relative humidity
[64]. During the measurement of mechanical strength using
texture analyzer, it was found that the contact time, contact
force, and the speed of probe withdrawal markedly influence
the experimental outcome [74]. The tensile strength is calcu-
lated by using several parameters such as folding endurance,
percent elongation, elongation at break and Young’s modulus.
7.2.1. Folding endurance
The flexibility of thin film is important when considering that
the films can be administered without breakage. The flexibil-
ity of the polymeric thin films can be measured with respect
to its folding endurance. The folding endurance is deter-
mined by folding the film repeatedly at 180° angle of the plane
at the same place until it breaks. The film exhibiting folding
endurance value of 300 or more is considered to have excel-
lent flexibility [75].
7.2.2. Percent elongation and elongation at break
Elongation, a kind of deformation, is a simple change in shape
that any objects encounter under any applied stress. In other
Fig. 5 – Examples of stress–strain curves obtained from
polymeric thin films (reproduced from Ref. [11]).
Fig. 6 – Experimental setup (left) and sample holder for the film preparation (right), where rs indicates radius of samples,
and rp indicates radius of probe. Geometry of cylindrical probes A and B and spherical probe C is shown on the right bottom
(reproduced from Ref. [64]).
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words, when the sample is subjected to tensile stress, defor-
mation of the sample takes place resulting in stretching or
elongation of sample [17]. Measurement of elongation is gen-
erally done to predict the ductility of polymers [65]. Elastic
elongation or elongation at break of a sample can be mea-
sured by using a texture analyzer. Elastic elongation is a
phenomenon shown by all kinds of elastomers. The percent
elongation indicates the stretch ability of material without being
broken, whereas elongation at break means the point until
which the film can be stretched when it is torn (or broken) by
the applied probe (Fig. 7).With the exertion of stress to a sample,
strain generates, and the sample elongations will become more
predominant as the amount of stress applied increases. After
reaching a certain point, the sample breaks; this point of break-
age is referred to as percent elongation break [76]. The formula
for percent elongation is given in Eq. (2) as under:
% Elongation
Increased length of film
Initial length of film
= × 100 (2)
Elongation at break can also be calculated by using follow-
ing formula as well:
Elongation at break
a b r
a
%( ) = ′ + + −⎛⎝⎜
⎞
⎠⎟ ×
2 2 2
1 100 (3)
where a is the initial length of the film in the sample holding
opening, a’ is the length of the film not punctured by the probe,
b is the penetration depth/vertical displacement by the probe,
and r is the radius of the probe (Fig. 7) [64].
7.2.3. Young’s modulus
Young’s modulus or elastic modulus reflects the stiffness or
elasticity of the films. This indicates resistance to deforma-
tion of the films, which can be calculated by plotting the stress
strain curve, where slope indicates the modulus, i.e. the greater
the slope, the greater would be the tensile modulus. On the
other side, the small slope means lesser tensile modulus and
deformation [77]. Simply, a film, exhibiting higher tensile
strength and greater Young’s modulus values, is the one that
is hard and brittle with small elongation. Texture analyzer can
be used for the measurement of Young’s modulus, where slope
is obtained from the stress strain curve. Young’s modulus is
represented as the ratio of applied stress over strain in the
region of elastic deformation, which can be determined using
the following formula:
Young’s modulus
Slope
Film thickness Crosshead speed
=
×
× 100
(4)
A range of crosshead speed can be obtained by changing
the speed of the motor of the texture analyzer [15].
7.2.4. Tear resistance
The property of the film to withstand the rupture is known as
tear resistance. The measurement of tear resistance is done
by allowing the film to undergo a constant rate of deforma-
tion. The maximum force or stress needed to tear the film is
measured in Newton or pound-force [17]. In a stress strain curve,
the area of the plot measures the tear resistance. The rela-
tion of an area under the stress strain curve is directly
proportional to the toughness of the film, i.e. higher area of
the plot means higher toughness of the film and also greater
amount of energy that a material can absorb.Therefore, it mea-
sures the strength of the material rather than toughness. In
fact, a less strong material can be tougher compared with a
strong material and no confusion should be created [12].
7.3. Moisture content
The amount of moisture in the film could be crucial as it affects
the mechanical strength, adhesive properties, and friability of
film [78]. Several factors are responsible for elevating water level
such as hygroscopic properties of API, polymers, and solvent
system used to dissolve the polymeric mixture, and manu-
facturing techniques. In general, the moisture content of the
film is determined by using several methods like Karl Fischer
titration or by weighing method. In weighing method, pre-
weighed films (initial weight) are heated at a temperature of
100–120 °C until they attain constant weight. Finally, the weight
of the final dried sample is taken. Eq. (5) is used for calculat-
ing the amount of moisture content in the film that is expressed
as % moisture and is given below [12]:
Moisture content
Initial weight Final dried weight
Ini
%( )
=
−( )
tial weight
⎡
⎣⎢
⎤
⎦⎥ × 100 (5)
7.4. Swelling
Swelling properties of films are generally observed as the poly-
mers employed for making films are hydrophilic [79]. Swelling
of the polymers is known to be the fundamental step re-
quired for bioadhesion [80,81]. In many cases the degree and
rate of swelling play a key role in controlling the release of the
drug. Hence, these parameters can be considered as the indi-
cator for bioadhesive or mucoadhesive potential and drug
release profiles. The testing of swelling is done to measure
polymer hydration [82]. Hydrophilic polymers with different
structures possess a varying degree of swelling based on the
Fig. 7 – Determination of percent elongation of thin films
using a texture analyzer, where a = initial length of the film
in the sample holder opening, a’ = initial length − radius of
probe, b = displacement of the probe, c’ + r = length after
strain, c’ = length of a’ after strain, r = radius of the probe
[64].
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relative resistance of matrix network structure to water mol-
ecule movement. For example, a polymer chain having the low
ability to form hydrogen bond is unable to form a strong
network structure, and water penetration is also difficult to
occur. When the number of hydrogen bonds as well as the
strength between the polymers increase, the diffusion of water
particles into the hydrated matrix occurs at a slow rate [83].
This was demonstrated by Panomsuk et al., where it was re-
ported that the introduction of mannitol to methylcellulose
matrix decreases the swelling index of the membrane.This may
be due to the formation of hydrogen bonding between drugs
and the polymeric matrix [84].
Measuring swelling or degree of hydration of the polymeric
film plays an important role in providing key information on
the mucoadhesive strength. As we know, the hydration of poly-
mers is the reason for relaxation and interpenetration of polymeric
chain; however, the overhydration results in a decrease of
mucoadhesion properties due to formation of slippery muci-
lage [85]. The swelling properties of films, i.e. water absorption
capacities, are measured by evaluating the percentage of hy-
dration. For example, the piece of films is weighed (W1) and it
is subjected to immersion in simulated physiological fluid for a
predetermined time. After the predetermined time, the sample
is taken out, wiped off to remove excessive water on the surface
and weighed (W2). The calculation is done by using the follow-
ing formula, which is expressed in % [83,86].
Hydration
W W
W
%( ) = ×−2 1
1
100 (6)
Furthermore, area swelling ratio (ASR) can be used to de-
termine the swelling property of the prepared films. As a
procedure, the films are placed in a Petri dish and 100 ml quan-
tity of phosphate buffer (pH = 7.4) was poured into it as a
swelling fluid. The diameter of a film is calculated at certain
time intervals. The calculation of ASR is based on Eq. (7) [87].
ASR
A
A
t
o
= (7)
where At is area of the film at time t, and A0 is area of the film
at time zero.
7.5. Drug release profiles
To a great extent, the release kinetics of drugs from the polymer
matrix is primarily dependent on the physicochemical properties
of the materials used as well as the morphology of the system
[36].Variation in pH or temperature may cause increase or de-
crease in the erosion or dissolution rates of polymers [88]. Upon
contact with biological fluids, the polymeric film starts to swell
following polymer chain relaxes, resulting in drug diffusion.
The release of drug holds a direct relationship with polymer
structure; for example, linear amorphous polymers dissolve
much faster than cross-linked or partially crystalline polymers
[89].According to several studies, the release of the drug is mark-
edly influenced by erosion of the film. The degradation rate of
the film is also dependent on the types of plasticizer [11]. For
the drug to penetrate the biological membrane, the drug should
be released from the delivery systems at an optimum rate.
Assessing the drug release from the film is essential as it is
the rate-determining step in the process of absorption.The dis-
solution of drugs and/or films is assessed with the apparatus
that is approved for other solid dosage forms [90].
In the literature, many authors have done some improvi-
sation on the dissolution apparatus, while others have employed
Franz diffusion cells (FDC) for testing the drug release from the
polymeric films [12]. A major barrier with respect to film in dis-
solution testing is the placing of the samples. Several methods
have been practiced, where the film is attached on the inner
side of the glass vessels or the stirring element using an ad-
hesive tape [24]. Okamoto et al. conducted a dissolution study
of lidocaine film for buccal administration using a JP XIII dis-
solution apparatus at 37 ± 0.1 °C. A film was cut into a circle
having an area of 1 cm2 and adhered to a 3 cm diameter weight
using double adhesive tape. Then, the film with weight was
placed in a glass vessel filled with 500 ml of artificial saliva so
that the film dosage form faces upwards as shown in Fig. 8 [91].
7.6. Surface morphology
The morphology of the film should appear homogeneous and
continuous to ensure the uniform distribution of drug through-
out the polymeric mixture. Self-aggregation might take place
during drying because of the intermolecular and convective
forces leading to wrinkled surface in films. Additionally,
interaction between drug and polymers, and the crystalline
nature of the drug, may result in the formation of rough surface
in the films [92]. Hence, assessing the surface morphology and
texture is crucial to assure uniform distribution of drugs without
any interaction with the polymers in the film formulation.
Various surface characteristics such as surface texture (smooth
or rough), thickness, and drug distribution (aggregated or scat-
tered) of the film can be observed using light microscopy,
scanning electron microscopy (SEM), transmission electron mi-
croscopy (TEM) and related imaging techniques [83]. Among
all, the scientists have more clung to SEM as a reliable method
for examining the surface morphology of the films. The op-
eration is carried out by mounting the films on stubs, sputter
coated with gold in an inert environment, and subsequently
Fig. 8 – Schematic illustration of the apparatus used for
dissolution studies of films. The film dosage form (1 cm2)
was attached to a 3 cm diameter weight using double
adhesive tape (reproduced from Ref. [91]).
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the photographs are taken at a suitable magnification. This ap-
proach can be utilized for close observation of size, shape and
the number of pores on the surface of polymeric films. Most
recently, there are a number of studies on the use of SEM in
evaluating the role of chemical composition of the film on the
crystallinity, morphology and texture [12].
8. Packaging of thin films
Packaging is crucial to provide mechanical protection as well
as to keep the stability of thin film formulations. It acts as a barrier
to the moisture, light, and oxygen.A number of choices are avail-
able for packaging the polymeric thin films,but not all are effective
to preserve the integrity and physical properties of the product.
Aluminum foils are most commonly used and considered ideal
for film packaging as it prevents the film from moisture and light
degradation. Similarly, lidding foil has been employed if tamper
proof packaging is needed. Films are subjected to multi-track
sealing to achieve an accurate airtight seal between the upper
and lower pack foils [17].The most commonly available sizes of
films are 3 × 2 cm2 and 2 × 2 cm2.The packaged films are checked
thoroughly before being packed into a secondary packaging con-
tainer [22]. The packing of manufactured film in foil, paper or
plastic pouches is cost-effective, easy to handle, and allows easy
formation of the flexible pouch by either vertical or horizontal
forming method during product filling [4].
Nowadays, the strips are available in both single dose sachets
and multiple-unit blisters. A single dose sachet with a name
Pocketpaks™ for cool mint Listerine was introduced by Pfizer
consumer healthcare. Similarly, a tear notch/slit/cut-off is manu-
factured to ensure convenience for the consumer to peel-off
the pack. This technique is automated and computer-driven
process [17]. APR-Labtec launched a patented packaging system
with the name Rapid card for the Rapid® films. The rapid card
has same size as a credit card and contains three films on each
side, which can be removed individually [22].
9. Routes for the administration of thin films
9.1. Oral route
Developing polymeric films has made it possible to improve
the drug bioavailability and patient adherence to drug therapy
via the oral route, especially buccal and sublingual route. The
anatomical and physiological characteristics of buccal mucosa,
such as the existence of smooth muscles with high vascular
perfusion, easy accessibility, and bypassing of first pass me-
tabolism make it a favorable route for the drug delivery [72].
The oral cavity consists of lips, cheek, tongue, hard palate, soft
palate and floor of the mouth [2]. Fig. 9 demonstrates the
common site for administration of films to buccal and sub-
lingual mucosa. Compared with the other mucosa, the buccal
and sublingual routes are preferable because it provides better
permeability of the drug [94].
Lesch and co-workers reported the water penetration across
the buccal mucosa to be 10 times higher than skin [95]. Similarly,
the oral mucosa was found to be 4–4000 times more permeable
to a hydrophilic drug than the skin [96]. The sublingual route
is targeted for the delivery of drug exhibiting high permeabil-
ity across the mucosa and is utilized for the treatment of acute
disorders. On the other hand, the buccal route is preferred for
the treatment of chronic disease, when an extended release
of the drug is desired [18]. Direct access to the systemic cir-
culation through the internal jugular vein is possible with buccal
drug delivery [36].
However, systemic drug delivery in the oral cavity may be
extremely challenging due to an unfavorable oral environ-
ment and physiological barriers. For achieving a promising
therapeutic effect, the drug must be released from the formu-
lation to the delivery site (e.g. sublingual or buccal region) and
should penetrate the oral mucosa to reach the systemic cir-
culation.The existence of several environmental related factors
such as fluid volume, pH, enzyme activity and the permeabil-
ity of oral mucosa determines the fate of drug absorption in
the oral mucosa. On the other side, the amount of secretion
of saliva impedes the residence of drug at the delivery site due
to washing out of the drug. Similarly, the swallowing of drugs
might occur before the absorption of the drug through the oral
mucosa [2,93]. Hence, while developing the oral formulation
like polymeric films, all the point should be taken into account
for obtaining higher therapeutic bioavailability as well as the
patient adherence to the dosage form.
Films containing the polymeric blend would be an ideal plat-
form for the delivery of drugs in the oral cavity because of its
comfort and flexibility [97]. Over the last decade, there has been
an enormous rise in the development of buccal films as an
alternative drug delivery for various classes such as anti-
inflammatory, analgesics, anesthetic drugs and proteins and
peptides. Of recent, mucoadhesive films have been used as
a delivery platform for transmucosal buccal delivery of
Biopharmaceutics Classification System (BCS) Class II drugs
particularly targeting the opioid analgesics like fentanyl citrate,
which is available with a trademark name such as Onsolis®/
Breakyl® for treating immense pain [26]. Similarly, the
mucoadhesive film remains attached to the buccal area without
Fig. 9 – Demonstration of common site for application of
film in buccal and sublingual mucosa (reproduced from
Ref. [93]).
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showing any erratic absorption profile, resulting in less inter-
and intra-individual variability [72]. Oral thin films (OTFs) are
comparable to the disintegrating system,which is soaked in saliva
and stick to the site of application. The rate of disintegration
is rapid, allowing the drug to release and followed by the
oromucosal absorption. Many drugs that undergo degradation
in the GI tract are being administered employing this route [98].
In context to the commercially marketed product of the oral
thin film, the nutraceuticals and over-the-counter drugs were
among the first to be introduced in the market, and included
the incorporated active such as vitamins, herbal and non-
herbal extracts. In 2001, Pfizer introduced a thin film product
of Listerine Pocketpaks® developed as mouth freshener. The
company Bio-film has been putting an endeavor to develop oral
thin films. Not only the pharmaceuticals but they are also using
nutraceuticals such as vitamins, aphrodisiac, energy boost-
ers, and appetite suppressor that targets a specific population
of the certain age group. The energy booster consists of various
compounds such as caffeine, guarana, and green tea extract
to maintain the energy levels [17]. A number of companies have
been attempting to develop a drug delivery platform based on
polymeric films. Most of them have already succeeded in ob-
taining a film with rapid release along with better therapeutic
outcomes [2]. The companies with their technology platform
based on polymeric film are listed in the Table 2.
9.2. Ocular route
More than 90% of the marketed ocular formulations are in the
form of solutions or suspension; however, this conventional
dosage form lacks in achieving promising therapeutic success
[99]. The frequent instillation of eye drops is needed to elicit
a therapeutic response. This usually leads to patient non-
compliance and pulsed administration. Furthermore, the
topically applied drugs to the eye generally enter the sys-
temic circulation via the nasolacrimal duct system, which
possibly cause side effects and systemic toxicity as well [100].
With the aim of enhancing the ocular bioavailability and over-
coming the ocular drug delivery barriers, the development of
ophthalmic film becomes popular these days [84]. The oph-
thalmic films result in the reduction of dose frequency, less
systemic side effects and better therapeutic outcomes. There-
fore, ophthalmic films could open exciting opportunities as a
delivery platform of therapeutics to replace the traditional
dosage forms for achieving high therapeutic success and patient
adherence. So far, the list of drugs formulated in ophthalmic
films is presented below in Table 3.
The flow of tear across the outer surface of the cornea is
continuous, which impedes the drug diffusion leading to low
bioavailability (1–7%) of drugs [108]. Generally, the drug with
higher lipophilicity encounters many problems as it cannot be
dissolved in the aqueous medium of the eye. Since the drug
causes discomfort in the eye, it induces blinking, and there-
fore causing washing out of the significant amount of drug.
Therefore, the success of the effective development of films
to be delivered to the eye relies on the comprehensive knowl-
edge of the drug, the constraints to ocular drug delivery, and
the excipients used. Hence, all these factors should be con-
sidered during the formulation of ocular films.
9.3. Transdermal route
Drug-loaded transdermal films are the alternative to replace
the existing transdermal dosage form. Numerous sustained or
controlled delivery systems have been devised, where a drug
is either dissolved or dispersed in the films [71]. The film-
forming system has been practiced for the transdermal delivery
of steroidal hormones, analgesics, local anesthesia and anti-
emetic for systemic effects [109–111].
Only a small number of drugs are being designed for the trans-
dermal delivery of films as several factors affect the bioavailability
of drug such as molecular size, polarity, pH of the drug, state of
the skin hydration, subcutaneous reservoir of drug and drug
metabolism by skin flora [112]. Similarly, the hydration of skin
is crucial for increasing drug absorption, which is possible by
using humectant in the film formulation.The physiological factors
such as regional skin site, nature of stratum corneum, the
thickness of skin, and density of appendages also influence the
overall outcome of the therapeutic effects of the drug [113].
Table 2 – List of commercialized thin films for drug delivery.
Company Brand name Type of formulation References
Labtec Pharma Zolmitriptan Rapidfilm® Zolmitriptan oral disintegrating films (ODF) [21]
BioAlliance Pharma Setofilm® Ondansetron ODF
MonoSol Rx and KemPharm KP106 D-amphetamine ODF
BioDelivery Sciences
International
OnsolisTM Fentanyl buccal soluble films [11]
Labtec Pharma RapidFilm® Ondansetron and donepezil ODF [2]
Novartis Triaminic Thin Strips Phenylephrine and diphenhydramine ODF [55]
MonoSol Rx Suboxone® Buprenorphine and naloxone (sublingual film)
C.B. Fleet Pedia-LaxTM Quick Dissolve Strip Sennosides ODF
Novartis Consumer Healthcare Gas-X Thin Strips Simethicone (sublingual film)
Pfizer Sudafed PE quick dissolve strips Phenylephrine ODF
Table 3 – List of drugs used in ocular films.
Active agent in ocular film References
Acetazolamide [101]
Timolol maleate [102]
Ofloxacin [103]
Dorzolamide hydrochloride [104]
Levofloxacin [78,105]
Naphazoline HCl [106]
Natamycin [107]
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The thin film may possess better therapeutic efficacy and
patient acceptance compared to the common transdermal
dosage forms such as patches or gels [114]. Due to occlusive
properties of transdermal patches, it prevents the perme-
ation of water vapor from the skin surface and causes severe
pain at the time of peeling. However, polymeric thin films could
be a highly promising alternative for transdermal drug deliv-
ery because of the ease of application, flexibility and better
cosmetic appearance [29].
10. Future scope of development
and conclusion
The formulation of a drug into various films has been popular
in recent years. Several undesirable drawbacks associated with
conventional dosage forms such as inconvenience of admin-
istration, lower bioavailability and patient non-compliance have
pushed the development of novel polymeric thin films as a drug
delivery platform. This drug delivery platform is being under
surveillance from both start-up and established pharmaceu-
tical companies. The companies strive to design a wide range
of thin films for oral, buccal, sublingual, ocular and transder-
mal routes. Therefore, as an alternative to conventional dosage
forms, polymeric thin films are expected to stand out as a
dosage form to overcome the limitations posed by existing
dosage forms. The film dosage form encounters several chal-
lenges during the phases of formulation development and
manufacture. Such issues should be addressed to optimize the
overall formulation even after transferring to large-scale manu-
facturing. The future looks very promising for the film
technology in the time to come as new technologies are rapidly
introduced to prepare thin films.
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